MR
MRKR.US Marker Therapeutics Inc
- Market cap
- USD 13.8M
- P/E
- -
- P/B
- 1.24x
- ROE
- -82.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is MRKR.US undervalued?
Graham numberThe Graham number of Marker Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Marker Therapeutics Inc fundamental analysis
No fundamental analysis for Marker Therapeutics Inc yet.
Marker Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Marker Therapeutics Inc
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601…
Full company profileMarker Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Marker Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 183K | 206K | 213K | 467K | 1.24M | 3.51M | 3.31M | 6.59M | 3.55M | 0.00 |
| Gross Profit | 0.00 | -5.07M | -124M | -12.6M | -18.4M | -1.92M | -8.45M | -7.11M | -6.88M | - | - |
| Operating Income | -8.49M | -11.5M | -148M | -22.5M | -28.9M | -39.5M | -19.8M | -14.6M | -11.1M | -12.9M | -13.4M |
| EBITDA | 6.04M | 183K | 206K | -22.2M | -27.6M | -38.7M | -16.1M | -11.3M | -10.7M | -12.4M | -10.0M |
| Net Income | -2.46M | -11.0M | -148M | -21.4M | -28.7M | -41.9M | -29.9M | -8.24M | -10.7M | -12.2M | -10.0M |
| EPS | -0.33 | -12 | -78 | -4.70 | -6.10 | -5.47 | -3.58 | -0.94 | -1.20 | -0.79 | -0.52 |
| Balance Sheet | |||||||||||
| Total Assets | 7.92M | 5.18M | 62.1M | 46.4M | 45.6M | 68.1M | 34.4M | 17.1M | 22.0M | 19.1M | 14.6M |
| Total Liabilities | 1.74M | 1.52M | 2.80M | 2.27M | 18.3M | 24.1M | 14.8M | 3.07M | 3.46M | 2.27M | 2.42M |
| Shareholders' Equity | 6.18M | 3.66M | 59.3M | 44.1M | 27.3M | 44.0M | 19.6M | 14.1M | 18.6M | 16.8M | 12.2M |
| Cash & Short-term Investments | 7.85M | 5.13M | 61.7M | 43.9M | 21.4M | 42.4M | 11.8M | 15.1M | 19.2M | 16.1M | 11.3M |
| Total Debt | 5.00K | 5.00K | - | 484K | 12.3M | 11.9M | 7.62M | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -6.51M | -8.44M | -14.5M | -18.3M | -20.0M | -27.3M | -27.0M | -16.4M | -10.9M | -12.0M | -10.2M |
| Capital Expenditure | 148K | 148K | 148K | 375K | 9.25M | 3.13M | 3.00 | 1.00 | 4.00 | 1.00 | 4.00 |
| Free Cash Flow | -6.51M | -8.44M | -14.6M | -18.7M | -29.3M | -30.4M | -27.0M | -16.4M | -10.9M | -12.0M | -10.2M |
| Ratios | |||||||||||
| ROE | -39.7% | -300.2% | -249.3% | -48.6% | -105.0% | -95.2% | -152.7% | -58.6% | -57.8% | -72.4% | -82.3% |
| ROA | -31.0% | -212.0% | -238.1% | -46.2% | -62.9% | -61.5% | -87.0% | -48.1% | -48.7% | -63.8% | -68.6% |
| Net Profit Margin | - | -5,999.0% | -71,826.4% | -10,050.9% | -6,149.7% | -3,372.7% | -851.9% | -248.8% | -162.8% | -343.0% | - |
| Debt to Equity | 0.00x | 0.00x | - | 0.01x | 0.45x | 0.27x | 0.39x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Marker Therapeutics Inc dividends
Marker Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Jan 27, 2023.
Who owns Marker Therapeutics Inc
- Insiders 5.49%
- Institutions 23.61%
- Public & others 70.90%
- Shares outstanding 16.7M
- Free float 13.7M
Top funds holding MRKR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 298K | 1.79% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 71.4K | 0.43% | -0.38% | Sep 2026 |
| Fidelity Series Total Market Index | 19.4K | 0.12% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 12.8K | 0.08% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 3.61K | 0.02% | 0.00% | Aug 2026 |
| Vanguard U.S. Eq Idx £ Acc | 2.51K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding MRKR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| NEA Management Company, LLC | 1.63M | 9.75% | 0.00% | Jun 2026 |
| Blue Owl Capital Holdings LP | 554K | 3.32% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 426K | 2.56% | +9.47% | Jun 2026 |
| Aisling Capital Management LP | 325K | 1.95% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 267K | 1.60% | +7.19% | Sep 2026 |
| Geode Capital Management, LLC | 140K | 0.84% | -13.11% | Jun 2026 |
| Advisor Group Holdings, Inc. | 113K | 0.68% | +20.97% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 87.3K | 0.52% | 0.00% | Jun 2026 |
| LPL Financial Corp | 83.1K | 0.50% | +0.12% | Jun 2026 |
| Two Sigma Investments LLC | 60.2K | 0.36% | -1.31% | Jun 2026 |
| XTX Topco Ltd | 45.4K | 0.27% | -28.65% | Jun 2026 |
| Northern Trust Corp | 34.6K | 0.21% | +33.14% | Jun 2026 |
| Citadel Advisors Llc | 32.5K | 0.20% | 0.00% | Jun 2026 |
| State Street Corp | 20.9K | 0.13% | 0.00% | Jun 2026 |
| Invst LLC | 18.0K | 0.11% | -37.93% | Jun 2026 |
| Creative Planning Inc | 17.3K | 0.10% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 16.8K | 0.10% | -53.63% | Jun 2026 |
| Virtu Financial LLC | 11.6K | 0.07% | 0.00% | Jun 2026 |
| Fifth Third Bancorp | 10.0K | 0.06% | 0.00% | Jun 2026 |
| UBS Group AG | 8.15K | 0.05% | -74.82% | Jun 2026 |
Marker Therapeutics Inc company profile
- Company name
- Marker Therapeutics Inc
- Ticker
- MRKR.US
- Exchange
- USA Stocks
- Listed since
- Mar 25, 2014
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Fiscal year end
- December
- Address
- 2450 Holcombe Blvd, Houston, TX, United States, 77021
- Phone
- 713 400 6400
- Website
- markertherapeutics.com
About Marker Therapeutics Inc
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.
Marker Therapeutics Inc management
7- Dr. Juan F. Vera M.D.Co-Founder, CEO, President, Treasurer, Secretary & Director · born 1980
- Ms. Elizabeth DonnellyDirector of Administration
- Dr. Maria-Bernadette Madel Ph.D.Director of Corporate Operations & External Communications · born 1990
- Mr. Edmund CheungVice President of Human Resources
- Patricia AllisonHead of Clinical Operations
- Ms. Mary Newman Ph.D.Head of Regulatory Affairs · born 1959
- Dr. Robert Z. Florkiewicz Sr., Ph.D.Senior Director of Molecular Biology & Virology